Compass Capital

(Est. 2010)

Compass is a leading private equity firm focusing on value investing. The firm’s multi- disciplinary team has a long and successful track record of generating attractive investment returns having successfully executed numerous transactions requiring capital flexibility, financial restructuring, and operational turnaround. Compass follows a disciplined investment approach that hinges on defining strategic initiatives, agile implementation of strategy, supporting talented management, and providing required growth capital to drive growth.

company is a principal investor in its own transactions and actively works to ensure that the interests of all stakeholders are aligned in the investments it pursues.

Current portfolio companies

Bonyan - Acquired 2018 (Stake 100%)
In July 2018 a subsidiary of Compass Investment acquired a 100% stake of Bonyan for Development & Trade from Qalaa Holdings subsidiary MENA Home Furnishings. Bonyan, a specialty real estate developer operating in Egypt, is the owner of the award-winning Designopolis mall, originally developed as a specialty furniture mall. Designopolis is an open-air asset designed by renowned architectural firm Skidmore, Owings and Merrill built on a 117,000 square meter plot of land located in West Cairo in the Sheikh Zayed area. Compass will repurpose the approximately 1 km long promenade of some 300 shops into a complete lifestyle destination that includes shopping, dining, office space and entertainment activities for the entire family.
Rameda – Acquired 2011 (Stake: 100% Compass & LPs)
In 2011, Compass Capital led a consortium that acquired 100% of the Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda), a leading Egyptian pharmaceutical company with a broad portfolio of human and veterinary products. Compass Capital’s specific initiatives have enabled the company to achieve significant milestones. Rameda has consistently outperformed the top 15 pharmaceutical players in Egypt in terms of revenue growth on the back of its aggressive expansionary strategy. In 2017, the company delivered top-line growth of c.60%, with a three-year (2015-2017) CAGR of 47% vs. a market average of 17%. Rameda has successfully built a scalable platform supported by three primary pillars of people, product and production. The company boasts an encouraging pipeline of new molecules in attractive therapeutic areas, has already kicked-off in 2017 its second expansion drive which would increase capacities by 40% and is led by a capable and experienced management team that can deliver results.

Existed Investments

Gallery

Contact Us

2 Wadi El Nile St., Mohandessin, Giza - Egypt
(+202) 3305 0700
(+202) 3305 0711